Kim, Sooyong
Shiffman, Saul
Sembower, Mark A.
Funding for this research was provided by:
Juul Labs, Inc.
Article History
Received: 4 May 2022
Accepted: 12 September 2022
First Online: 19 September 2022
Declarations
:
: This is a secondary analysis of publicly available PATH data. The PATH study was conducted by Westat, Inc. and approved by Westat’s institutional review board (Project Number 8954, FWA 00005551). All analyses were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: SK, SS, and MAS provide consulting services on tobacco harm reduction on an exclusive basis to Juul Labs, Inc. through PinneyAssociates, Inc. SS holds a patent for a novel nicotine medication that has not been developed or commercialized.